Singer Philipp, Zhang Weining, Yee Benjamin K
Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology (ETH) Zurich, Schorenstrasse 16, Schwerzenbach, 8603, Switzerland.
Psychopharmacology (Berl). 2013 Nov;230(2):309-17. doi: 10.1007/s00213-013-3160-3. Epub 2013 Jun 5.
Inhibition of glycine transporter 1 (GlyT1) elevates extracellular glycine and can thus increase N-methyl-D-aspartate receptor (NMDAR) excitability in the brain. The potent GlyT1 inhibitor, SSR504734, has also been shown to potentiate the behavioral effects of direct and indirect dopamine agonists. Thus, an acute systemic dose of SSR504734 was sufficient to exacerbate the motor-stimulant effect of the dopamine releaser amphetamine in C57BL/6 mice, even though SSR504734 alone exerted no significant effect on motor activity.
Here, we explore if SSR504734 might modulate dopamine-dependent sensory gating in the paradigm of prepulse inhibition (PPI) of the acoustic startle reflex.
Experiment 1 characterized the effect of SSR504734 (10 and 30 mg/kg i.p.) on PPI expression when administered alone. Experiments 2 and 3 investigated the impact of SSR504734 when administered in conjunction with the dopamine receptor agonist, apomorphine (1 and 2 mg/kg s.c.), which is known to reliably disrupt PPI.
When administered alone, acute SSR504734 enhanced PPI only at 30 mg/kg--a dose that has been shown to improve cognitive functions including working memory, which has been linked to enhanced NMDAR function resulting from the elevation of extracellular glycine. However, this effect did not allow SSR504734 to antagonize the PPI-disruptive effect of apomorphine. At the lower dose of 10 mg/kg--that was insufficient to enhance PPI when administered alone--SSR504734 even exacerbated the deleterious effect of apomorphine on PPI.
The therapeutic potential of GlyT1 inhibition against distinct behavioral/cognitive deficiency might require different magnitudes of GlyT1 inhibition.
抑制甘氨酸转运体1(GlyT1)可提高细胞外甘氨酸水平,从而增加大脑中N-甲基-D-天冬氨酸受体(NMDAR)的兴奋性。强效GlyT1抑制剂SSR504734也已被证明可增强直接和间接多巴胺激动剂的行为效应。因此,即使SSR504734单独对运动活动没有显著影响,急性全身剂量的SSR504734也足以加剧多巴胺释放剂苯丙胺对C57BL/6小鼠的运动刺激作用。
在此,我们探讨SSR504734是否可能在听觉惊吓反射的前脉冲抑制(PPI)范式中调节多巴胺依赖的感觉门控。
实验1表征了单独给予SSR504734(10和30mg/kg腹腔注射)对PPI表达的影响。实验2和3研究了SSR504734与多巴胺受体激动剂阿扑吗啡(1和2mg/kg皮下注射)联合给药时的影响,已知阿扑吗啡会可靠地破坏PPI。
单独给药时,急性SSR504734仅在30mg/kg时增强PPI,该剂量已被证明可改善包括工作记忆在内的认知功能,这与细胞外甘氨酸升高导致的NMDAR功能增强有关。然而,这种作用并不能使SSR504734拮抗阿扑吗啡对PPI的破坏作用。在10mg/kg的较低剂量下,单独给药时不足以增强PPI,SSR504734甚至加剧了阿扑吗啡对PPI的有害作用。
抑制GlyT1对不同行为/认知缺陷的治疗潜力可能需要不同程度的GlyT1抑制。